



US009249173B2

(12) **United States Patent**
Sommadossi et al.

(10) **Patent No.:** **US 9,249,173 B2**
(45) **Date of Patent:** **Feb. 2, 2016**

(54) **COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS**

(71) Applicants: **Idenix Pharmaceuticals, Inc.**,
Cambridge, MA (US); **Centre National de la Recherche Scientifique**, Paris (FR); **Universite Montpellier II**, Montpellier (FR)

(72) Inventors: **Jean-Pierre Sommadossi**, Cambridge, MA (US); **Gilles Gosselin**, Montpellier (FR); **Claire Pierra**, Montramaud (FR); **Christian Perigaud**, Grabels (FR); **Suzanne Peyrottes**, Grabels (FR)

(73) Assignee: **Idenix Pharmaceuticals, LLC**,
Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/197,078**

(22) Filed: **Mar. 4, 2014**

(65) **Prior Publication Data**

US 2014/0255339 A1 Sep. 11, 2014

Related U.S. Application Data

(60) Division of application No. 13/116,890, filed on May 26, 2011, now Pat. No. 8,691,788, which is a continuation of application No. 12/005,937, filed on Dec. 27, 2007, now Pat. No. 7,951,789.

(60) Provisional application No. 60/877,944, filed on Dec. 28, 2006, provisional application No. 60/936,290, filed on Jun. 18, 2007, provisional application No. 60/985,891, filed on Nov. 6, 2007.

(51) **Int. Cl.**

A61K 31/70 (2006.01)
C07H 17/02 (2006.01)
C07F 9/6558 (2006.01)
C07F 9/6561 (2006.01)
C07H 19/00 (2006.01)
A61K 31/675 (2006.01)
A61K 31/7056 (2006.01)
A61K 31/7064 (2006.01)
A61K 31/7068 (2006.01)
A61K 31/7072 (2006.01)
A61K 31/7076 (2006.01)
A61K 31/708 (2006.01)

(52) **U.S. Cl.**

CPC **C07H 17/02** (2013.01); **A61K 31/675** (2013.01); **A61K 31/708** (2013.01); **A61K 31/7056** (2013.01); **A61K 31/7064** (2013.01); **A61K 31/7068** (2013.01); **A61K 31/7072** (2013.01); **A61K 31/7076** (2013.01); **C07F 9/65586** (2013.01); **C07F 9/65616** (2013.01); **C07H 19/00** (2013.01)

(58) **Field of Classification Search**

USPC 514/50, 43
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,480,613 A 11/1969 Walton
5,627,185 A 5/1997 Gosselin et al.
6,174,868 B1 1/2001 Anderson et al.
6,284,458 B1 9/2001 Anderson et al.
6,348,587 B1 2/2002 Schinazi et al.
6,391,542 B1 5/2002 Anderson et al.
6,423,489 B1 7/2002 Anderson et al.
6,433,159 B1 8/2002 Anderson
6,455,513 B1 9/2002 McGuigan et al.
6,555,676 B2 4/2003 Gosselin et al.
6,566,365 B1 5/2003 Storer
6,573,247 B1 6/2003 McGuigan et al.
6,608,191 B1 8/2003 Anderson et al.
6,638,919 B2 10/2003 McGuigan et al.
6,653,296 B1 11/2003 Holy et al.
6,660,721 B2 12/2003 Devos et al.
6,752,981 B1 6/2004 Erion et al.
6,777,395 B2 8/2004 Bhat et al.
6,784,161 B2 8/2004 Ismaili et al.
6,784,166 B2 8/2004 Devos et al.
6,787,526 B1 9/2004 Bryant et al.
6,812,219 B2 11/2004 LaColla et al.
6,833,361 B2 12/2004 Hong et al.
6,846,810 B2 1/2005 Martin et al.
6,849,726 B2 2/2005 Usman et al.
6,852,535 B1 2/2005 Thompson
6,911,424 B2 6/2005 Schinazi et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 101333235 A 12/2008
EP 1655033 A1 10/2006

(Continued)

OTHER PUBLICATIONS

Ariza, "Current Prodrug Strategies for the Delivery of Nucleotides into Cells," Drug Design Reviews-Online, 2005, 2, 373-87.
Ariza, "Current Prodrug Strategies for the Delivery of Nucleotides into Cells," Drug Design Reviews-Online, 2005, 2, 373-387.
Ballatore, et al., "Synthesis and Evaluation of Novel Amidate Prodrugs of PMEA and PMPA," Bioorganic & Medicinal Chemistry Letters 11, 2001 1053-1056.
Beltran, et al., "Rational Design of a New Series of Pronucleotide," Bioorganic & Medicinal Chemistry Letters, 11, 2001, 1775-1777.
Birkus, Cathepsin A Is the Major Hydrolase Catalyzing the Intracellular Hydrolysis of the Antiretroviral Nucleotide Phosphonoamidate Prodrugs GS-7340 and GS-9131, Antimicrobial Agents and Chemotherapy, 2007, 543-550.
Cahard, et al., "Aryloxy Phosphoramidate Triesters as Pro-Tides," Mini-Reviews in Medicinal Chemistry, 2004, 4, 371-382.
Chapman, et al., "Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340," Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), 621-628, 2001.

(Continued)

Primary Examiner — Rei-Tsang Shiao

(74) Attorney, Agent, or Firm — Jones Day

(57) **ABSTRACT**

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

23 Claims, 2 Drawing Sheets